| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5690654 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
Celecoxib at 400Â mg once daily for 14-18Â weeks did not significantly decrease the severity of CIN 3 compared with placebo except, possibly, in subjects with high baseline VEGF. Therefore, serum VEGF levels might identify patients who may benefit from celecoxib or other therapies, personalizing future chemoprevention trials for CIN 3.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Janet S. Rader, Michael W. Sill, Jan H. Beumer, Heather A. Lankes, Doris Mangiaracina Benbrook, Francisco Garcia, Connie Trimble, J. Tate Thigpen, Richard Lieberman, Rosemary E. Zuna, Charles A. III, Nick M. Spirtos, John Byron, Premal H. Thaker,